Stock listing
NASDAQ:SCTX Scribe Therapeutics Inc. Stock
Follow Scribe Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SCTX
$12.07 USD -1.98 (-14.1%)
Close on Nov 20, 2026
- Day range
- $12.00 – $13.40 USDNov 20, 2026
- Volume
- 301,402 sharesNov 20, 2026
- Market cap
- $228.5M USDAt the close on Nov 20, 2026 · price × 18.93M shares outstanding
- Traded on an average day
- $8.82M USDMedian day 318,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SCTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.07 | -1.98 | -14.1% | $12.87 | $13.40 | $12.00 | 301,402 | |
| $14.05 | -1.72 | -10.9% | $15.78 | $16.34 | $14.00 | 271,910 | |
| $15.77 | +0.40 | +2.6% | $15.27 | $15.99 | $14.71 | 272,885 | |
| $15.37 | -0.99 | -6.1% | $16.53 | $17.25 | $15.30 | 435,090 | |
| $16.36 | -0.63 | -3.7% | $16.23 | $16.66 | $15.34 | 330,570 | |
| $16.99 | +0.13 | +0.8% | $16.37 | $17.45 | $15.55 | 282,118 | |
| $16.86 | -0.50 | -2.9% | $17.50 | $17.76 | $16.70 | 367,605 | |
| $17.36 | +0.68 | +4.1% | $16.42 | $18.30 | $16.01 | 343,281 | |
| $16.68 | +0.98 | +6.2% | $15.99 | $17.40 | $15.69 | 305,834 | |
| $15.70 | +0.22 | +1.4% | $15.60 | $16.44 | $15.29 | 321,589 | |
| $15.48 | -1.30 | -7.7% | $17.50 | $17.50 | $15.39 | 291,689 | |
| $16.78 | +0.58 | +3.6% | $16.58 | $17.48 | $16.25 | 263,055 | |
| $16.20 | +0.66 | +4.2% | $15.71 | $16.47 | $15.57 | 233,067 | |
| $15.54 | +0.12 | +0.8% | $15.58 | $15.87 | $14.31 | 332,056 | |
| $15.42 | -2.02 | -11.6% | $17.00 | $17.00 | $14.77 | 479,200 | |
| $17.44 | -0.10 | -0.6% | $17.45 | $18.27 | $16.98 | 252,800 | |
| $17.54 | +1.58 | +9.9% | $16.21 | $17.73 | $15.78 | 318,800 | |
| $15.96 | +0.36 | +2.3% | $15.81 | $16.32 | $15.15 | 578,600 | |
| $15.60 | +0.19 | +1.2% | $15.40 | $16.89 | $14.88 | 348,500 | |
| $15.41 | -2.55 | -14.2% | $17.88 | $18.55 | $15.12 | 861,500 | |
| $17.96 | -1.34 | -6.9% | $19.11 | $19.11 | $16.40 | 641,300 | |
| $19.30 | -0.51 | -2.6% | $20.43 | $21.00 | $19.00 | 485,300 | |
| $19.81 | +0.42 | +2.2% | $19.64 | $21.37 | $19.33 | 203,700 | |
| $19.39 | -0.69 | -3.4% | $20.09 | $20.92 | $18.27 | 259,400 | |
| $20.08 | -0.64 | -3.1% | $20.86 | $21.00 | $19.67 | 201,500 | |
| $20.72 | -0.05 | -0.2% | $20.79 | $21.95 | $19.73 | 180,900 | |
| $20.77 | +1.65 | +8.6% | $18.81 | $21.99 | $18.81 | 391,300 | |
| $19.12 | -1.55 | -7.5% | $20.28 | $20.28 | $18.00 | 298,500 | |
| $20.67 | -0.50 | -2.4% | $21.20 | $22.07 | $19.52 | 512,500 | |
| $21.17 | +1.94 | +10.1% | $19.21 | $21.33 | $19.18 | 396,500 | |
| $19.23 | +1.66 | +9.4% | $17.54 | $19.75 | $16.90 | 351,900 | |
| $17.57 | +1.24 | +7.6% | $15.94 | $18.16 | $15.75 | 420,500 | |
| $16.33 | +0.12 | +0.7% | $16.12 | $17.17 | $15.37 | 464,400 | |
| $16.21 | -0.58 | -3.5% | $17.17 | $17.17 | $13.50 | 1,106,500 | |
| $16.79 | -0.39 | -2.3% | $17.50 | $17.81 | $16.49 | 474,900 | |
| $17.18 | -1.23 | -6.7% | $18.41 | $19.36 | $17.00 | 669,200 | |
| $18.41 | -4.62 | -20.1% | $23.03 | $23.40 | $17.70 | 1,180,700 | |
| $23.03 | +1.26 | +5.8% | $21.53 | $23.75 | $21.29 | 671,200 | |
| $21.77 | +0.49 | +2.3% | $21.28 | $22.00 | $20.50 | 306,900 | |
| $21.28 | -0.33 | -1.5% | $23.17 | $23.28 | $20.21 | 458,500 | |
| $21.61 | -4.92 | -18.5% | $26.27 | $26.27 | $21.36 | 525,500 | |
| $26.53 | -1.54 | -5.5% | $28.51 | $29.09 | $26.08 | 532,700 | |
| $28.07 | +0.02 | +0.1% | $28.52 | $30.36 | $25.00 | 584,500 | |
| $28.05 | -4.95 | -15.0% | $32.88 | $34.49 | $27.32 | 528,600 | |
| $33.00 | +0.86 | +2.7% | $31.76 | $35.40 | $31.76 | 2,236,400 | |
| $32.14 | +3.04 | +10.4% | $29.44 | $33.36 | $29.30 | 303,900 | |
| $29.10 | -2.56 | -8.1% | $31.80 | $32.90 | $27.94 | 326,000 | |
| $31.66 | +2.24 | +7.6% | $30.19 | $32.02 | $28.85 | 161,500 | |
| $29.42 | -0.32 | -1.1% | $29.97 | $30.53 | $28.55 | 137,000 | |
| $29.74 | +0.27 | +0.9% | $29.76 | $31.00 | $29.02 | 141,200 | |
| $29.47 | +0.06 | +0.2% | $29.31 | $30.55 | $28.83 | 189,500 | |
| $29.41 | -1.93 | -6.2% | $30.59 | $32.16 | $29.14 | 153,200 | |
| $31.34 | +2.67 | +9.3% | $28.00 | $31.68 | $27.61 | 218,000 | |
| $28.67 | -2.14 | -6.9% | $30.21 | $31.45 | $28.50 | 147,900 | |
| $30.81 | -0.09 | -0.3% | $31.00 | $32.25 | $29.75 | 148,000 | |
| $30.90 | +1.90 | +6.6% | $29.75 | $32.41 | $29.67 | 278,700 | |
| $29.00 | -1.54 | -5.0% | $30.65 | $31.25 | $28.46 | 165,000 | |
| $30.54 | +2.10 | +7.4% | $28.39 | $31.61 | $27.20 | 151,100 | |
| $28.44 | -0.40 | -1.4% | $28.78 | $34.64 | $27.99 | 201,700 | |
| $28.84 | -2.86 | -9.0% | $31.29 | $31.66 | $27.54 | 194,700 | |
| $31.70 | +0.495 | +1.6% | $32.81 | $33.71 | $28.83 | 246,200 | |
| $31.21 | -6.045 | -16.2% | $38.00 | $38.60 | $30.75 | 316,029 | |
| $37.25 | +3.12 | +9.1% | $35.76 | $38.90 | $34.55 | 545,547 | |
| $34.13 | +1.30 | +4.0% | $33.90 | $36.89 | $33.90 | 179,400 | |
| $32.83 | +1.78 | +5.7% | $31.30 | $39.60 | $30.88 | 419,200 |
- Ticker
- NASDAQ:SCTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
Latest deck · 2026
Investor Presentation (2026)
Investor deck · 31 slides
Latest news
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
Nov 18, 2026
Closed $14.05 (-10.9%) on Nov 18, 2026
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Nov 12, 2026
Closed $16.36 (-3.7%) on Nov 13, 2026
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Nov 5, 2026
Closed $15.48 (-7.7%) on Nov 5, 2026
Scribe Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 18, 2026 · oldest 2026
- Decks
- 1 deck · latest 2026
Valuation
EV/sales 1.2× against a median of 11.9×: 4th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $59.42M USD
- P/E
- Loss
- EV/sales
- 1.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- −18.8%
- Operating margin
- −50.9%
- Net margin
- −42.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Scribe Therapeutics Inc. · NASDAQ:SCTX | US$228.5M | US$59.42M | n/a | 1.2× | n/a | 1.8× | −42.6% | 0.0× | n/a |
| Clinuvel Pharmaceuticals Limited · ASX:CUV | US$238.9M | US$73.38M | 10.3× | 1.1× | 2.6× | 1.3× | 36.0% | 0.0× | n/a |
| CAMP4 Therapeutics Corporation · NASDAQ:CAMP | US$237.8M | US$119.8M | n/a | 22.5× | n/a | 2.2× | n/a | 0.1× | 1.70 |
| Valerio Therapeutics · EURONEXT:ALVIO | US$228.9M | US$242.3M | n/a | 85.8× | 50.8× | n/a | −190.4% | n/a | n/a |
| Aprilbio Co., Ltd. · KRX:397030 | US$222.4M | US$162.1M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.6M | n/a | 404× | n/a | n/a | n/a | n/a | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| Median of the others | US$222.1M | US$140.1M | 10.3× | 11.9× | 26.7× | 1.3× | −130.5% | 0.1× | 1.17 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 57.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.63 · 1 analyst
- Revenue, year to Dec 2026
- 7.94M · 4 analysts
Team and board
| Officer | Role |
|---|---|
| Benjamin L. Oakes | Co-founder, President and CEO |
| David Parrot | Chief Financial Officer |
| Svetlana Lucas | Chief Operating Officer |
| Brett Staahl | Co-founder, VP of External Innovation |
| Chitra Sharma | SVP of Development |
| George Manning | VP, Controller |
| Sunny Mok | SVP of Operations |
| David F. Savage | Co-Founder, Scientific Advisor |
| James Watson | Head of Business and Corporate Development, Life Sciences Portfolio, Andreessen Horowitz |
| Jennifer A. Doudna | Co-founder, Scientific Advisor |
| Richard Hector | Head of IP |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −3.7% |
| Q2 2026 | Sep 2, 2026 · After close | −0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 31 slides | 2026 |
IPO
Priced at US$15.00 a share on Jul 23, 2026.
- Price
- US$15.00 a share
- Shares offered
- 8,580,000 shares of common stock
- Offering size
- US$128.7 million
- Underwriters' option
- Up to 1,287,000 more shares
- Listing
- SCTX on the Nasdaq Global Market
- Underwriters
- Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, Wells Fargo Securities · In the order on the cover
- Shares delivered
- On or about Jul 27, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 9, 2026 |
| Filed publicly | Jul 2, 2026 |
| Amended twice | Newest Jul 20, 2026 |
| Shares registered with an exchange | Jul 21, 2026 |
| Declared effective by the SEC | Jul 23, 2026 |
| Final prospectus, with the price | Jul 27, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 27, 2026 |
| FWP · Free writing prospectus | Jul 24, 2026 |
| EFFECT · Notice that a registration is effective | Jul 23, 2026 |
| S-1MEF · Registration of more shares for the same offering | Jul 23, 2026 |
| CERT · Exchange's certificate of listing | Jul 22, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 21, 2026 |
| S-1/A · Registration statement, amended | Jul 20, 2026 |
| S-1/A · Registration statement, amended | Jul 10, 2026 |
| S-1 · Registration statement | Jul 2, 2026 |
| DRS/A · Draft registration statement, amended | Jun 12, 2026 |
All 12 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Mar 6, 2026 |
| DRS · Draft registration statement | Jan 9, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 27, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 51.2M | 27.4M |
| Cost of revenue | 60.8M | |
| Gross profit | -9.62M | |
| Research and development | 60.8M | 57.1M |
| Selling, general and administrative | 16.4M | 13.2M |
| Operating income | -26.1M | -42.8M |
| Depreciation and amortization | 3.08M | 2.89M |
| EBITDA | -23.0M | -39.9M |
| Interest expense | 2.39M | 2.38M |
| Income before tax | -23.6M | -37.6M |
| Income tax | -1.80M | |
| Net income | -21.8M | -47.8M |
| Earnings per share, basic | -1.24 | -2.72 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 12.8M | 12.6M |
| Short-term investments | 45.2M | 92.6M |
| Receivables | 7.35M | |
| Current assets | 66.9M | 110.4M |
| Total assets | 78.2M | 128.0M |
| Accounts payable | 4.57M | 3.79M |
| Current liabilities | 69.1M | 35.0M |
| Long-term debt | 34.5M | |
| Total debt | 41.4M | |
| Total liabilities | 101.3M | 253.8M |
| Shareholders' equity | -23.1M | -125.9M |
| Shares outstanding | 17.6M | 17.6M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -45.2M | -45.2M |
| Capital spending | -1.27M | -1.35M |
| Free cash flow | -46.5M | -46.6M |
| Cash from investing | 45.3M | |
| Cash from financing | 142.0K | -222.0K |
| Change in cash | 194.0K | -32.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Sep 2, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 2, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
All 49 filings
Cap table
Built by 6ix from Scribe Therapeutics Inc.’s releases · as of Aug 31, 2026
- Common shares
- 18,931,680
- Fully diluted
- 18,931,680
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 18,931,680 | Aug 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 31, 2026 | 18,931,680 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Behzad Aghazadeh Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Aug 26, 2021); Immunomedics Inc (Director · Oct 23, 2020 – Oct 23, 2020 · Past) | Director · Since at least Jul 23, 2026 |
| Benjamin L. Oakes | Co-founder, President and CEO · Since at least Nov 4, 2026 |
| Brett Staahl | Co-founder, VP of External Innovation · Since at least Nov 5, 2026 |
| Chitra Sharma | SVP of Development · Since at least Nov 5, 2026 |
| David F. Savage | Co-Founder, Scientific Advisor · Since at least Nov 5, 2026 |
| David Parrot | Chief Financial Officer · Since at least Nov 5, 2026 |
| George Manning | VP, Controller · Since at least Nov 5, 2026 |
| James Watson | Head of Business and Corporate Development, Life Sciences Portfolio, Andreessen Horowitz · Since at least Nov 5, 2026 |
| Jennifer A. Doudna | Co-founder, Scientific Advisor · Since at least Nov 5, 2026 |
| Richard Hector | Head of IP · Since at least Nov 5, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Sunny Mok | SVP of Operations · Since at least Nov 5, 2026 |
| Svetlana Lucas | Chief Operating Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Scribe Therapeutics Inc.